Production of anti-CD20 intrinsic antibody and its use
Patent Information
- Authority / Receiving Office
- CN Β· China
- Current Assignee / Owner
- BEIJING MABWORKS BIOTECH
- Publication Date
- 2007-01-17
- Estimated Expiration
- Not applicable Β· inactive patent
Smart Images
Figure 1 Figure 2 Figure 3
Abstract
Description
technical field
[0001] The invention relates to a novel monoclonal antibody specifically targeting CD20 (named 1-28), which has the functions of recognizing CD20 molecules, inhibiting the growth of CD20 positive cells, and specifically killing target cells through CDC; Good prospects for clinical application.
[0002] The present invention relates to a novel humanized mouse monoclonal antibody method: the variable region of the antibody is ScFv; the constant region is the Fc segment of IgG, that is, the CH2 domain and CH3 domain of the antibody; the variable region and the constant region are connected through the hinge region of the antibody; Under natural conditions, the cysteine ββin the hinge region forms a disulfide bond and dimerizes into a bivalent structure. The anti-CD20 humanized antibody TGS achieved by this method greatly reduces the murine origin of mAb 1-28, while maintaining good antigen recognition activity and CDC function, and improves the clinical applicati...